A workflow for assessing antibody-drug conjugate target expression on circulating tumour cells from triple-negative breast cancer and epithelial ovarian cancer patients
{{output}}
Background: Antibody-drug conjugates (ADCs) are transforming the therapeutic landscape of solid tumours. Both patient selection and ADC efficacy in triple-negative breast cancer (TNBC) and epithelial ovarian cancer (EOC) are impa... ...
